GlassScriptPhysician profile
Maria Philip
NPI 1841429057
$3,623.92
in general payments reported to CMS, 2019-2025
38 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $300 · 2021: $564 · 2022: $724 · 2023: $641 · 2024: $352 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532 · Education: $10.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.90 |
| Education | $10.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $685.73 | 2019-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Abbvie INC. | $530.64 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $194.73 | 2019-2022 | |
| Pfizer INC. | $191.41 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $180.84 | 2020-2022 | |
| Amylyx Pharmaceuticals, INC. | $180.04 | 2023-2024 | Relyvrio |
| Novartis Pharmaceuticals Corporation | $170.97 | 2019-2024 | |
| Lilly USA, LLC | $139.24 | 2024-2025 | Kisunla, Emgality, Reyvow |
| Amgen INC. | $114.42 | 2019-2025 | Uplizna |
| Biogen, INC. | $100.70 | 2019-2023 | Skyclarys |
| Eisai INC. | $86.98 | 2019-2025 | |
| Ucb, INC. | $84.36 | 2019-2023 | Nayzilam |
| Merz Pharmaceuticals, LLC | $78.45 | 2022-2024 | Xeomin |
| Emd Serono, INC. | $76.04 | 2019-2021 | |
| Horizon Therapeutics Plc | $75.36 | 2021-2022 |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,600,758.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Philip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.